Keenova Presents a New TERLIVAZ® (terlipressin) Clinical Analysis at the SHM Converge

Rhea-AI Summary

Keenova Therapeutics (NYSE:MNK) will present new clinical analysis of TERLIVAZ (terlipressin) at the Society of Hospital Medicine Converge, March 29–April 1, 2026.

The presentation reports real-world utilization patterns and outcomes in hospitalized U.S. adults with hepatorenal syndrome‑acute kidney injury (HRS‑AKI). According to the company, TERLIVAZ is the first and only FDA‑approved therapy to improve kidney function in adults with HRS‑AKI. The study is a retrospective cohort authored by A. Sidney Barritt IV and colleagues.

Market Context

This announcement highlights additional real-world clinical analysis of TERLIVAZ in adults with HRS‑...

Analysis

This announcement highlights additional real-world clinical analysis of TERLIVAZ in adults with HRS‑AKI, presented at an upcoming SHM Converge meeting from March 29–April 1, 2026. It emphasizes expanding the evidence base for an FDA‑approved therapy rather than introducing new financial or regulatory milestones. With no recent news history or peer moves provided, investors may focus on future updates that quantify outcomes, utilization trends, and any subsequent regulatory or labeling implications.

Key Figures

Conference dates: March 29–April 1, 2026 Announcement date: March 27, 2026

2 metrics

Conference dates March 29–April 1, 2026 Society of Hospital Medicine (SHM) Converge presentation window

Announcement date March 27, 2026 Press release date for new TERLIVAZ clinical analysis

Key Terms

hepatorenal syndrome-acute kidney injury, HRS‑AKI, terlipressin, FDA‑approved, +1 more

5 terms

hepatorenal syndrome-acute kidney injury medical

"a new presentation on hepatorenal syndrome-acute kidney injury (HRS‑AKI) and TERLIVAZ"

A severe complication in people with advanced liver disease where the kidneys suddenly stop working because blood flow and body chemistry are altered by the failing liver. Think of the liver as a central pump that keeps pipes and filters supplied; when it fails, the kidneys (filters) can shut down even though they are not directly damaged. For investors, it matters because the condition drives urgent medical care, creates demand for specific drugs and devices, and is a common endpoint in clinical trials and regulatory decisions for liver- and kidney-related therapies.

HRS‑AKI medical

"patients affected by HRS-AKI."TERLIVAZ is the first and only FDA‑approved therapy"

HRS‑AKI (hepatorenal syndrome–acute kidney injury) is a sudden, severe loss of kidney function that occurs in people with advanced liver disease. It happens because changes in blood flow and circulation tied to liver failure cause the kidneys to stop working properly, even though the kidneys themselves are not initially damaged. Investors care because HRS‑AKI is life‑threatening, requires urgent treatment, drives hospital stays and high costs, and represents a focused clinical market for therapies and diagnostics.

terlipressin medical

"hospitalized U.S. adults With Hepatorenal Syndrome-Acute Kidney Injury Treated with Terlipressin"

Terlipressin is a prescription medicine that acts like a strong “squeeze” on blood vessels to raise blood pressure and redirect blood flow, commonly used to treat life‑threatening complications of advanced liver disease such as kidney failure linked to cirrhosis and severe bleeding from swollen veins. Investors track terlipressin because its trial results, regulatory approvals, safety signals and pricing determine market access and potential revenue for developers, while adverse effects or limited benefit can sharply affect a drug’s commercial prospects.

FDA‑approved regulatory

"TERLIVAZ is the first and only FDA‑approved therapy indicated to improve kidney function"

FDA-approved means a medical product, such as a drug, device, or diagnostic, has passed the U.S. Food and Drug Administration’s tests for safety and effectiveness for a specific use. For investors, approval is like receiving a highway permit: it clears major regulatory hurdles to sell the product widely, can unlock revenue and market access, and reduces uncertainty about legal and clinical risks.

retrospective cohort study medical

"Treated with Terlipressin: A Retrospective Cohort Study"

A retrospective cohort study is a research approach that looks back at existing records to compare outcomes for groups of people who were exposed to something (a drug, treatment, or risk factor) and those who were not. Think of it like reviewing past school report cards to see whether students who used a particular study method tended to do better; investors use these studies to judge the strength of evidence about safety or effectiveness, which can influence regulatory expectations, market confidence, and valuation risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, March 27, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that a new presentation on hepatorenal syndrome-acute kidney injury (HRS‑AKI) and TERLIVAZ^® (terlipressin) will be shared at the Society of Hospital Medicine (SHM) Converge, taking place March 29-April 1, 2026.

"We are pleased to share these findings with the medical community, as they help deepen our understanding of this challenging and rapidly progressive condition," said Dr. Marek Honczarenko, Executive Vice President and Chief Scientific Officer at Keenova. "Expanding the clinical evidence base is essential, and this analysis provides fresh insight into how clinicians are using TERLIVAZ in practice and how we can continue to support patients affected by HRS-AKI."

TERLIVAZ is the first and only FDA‑approved therapy indicated to improve kidney function in adults with HRS‑AKI.

Presentation Details

• Title: Real-World Utilization Patterns and Outcomes in Hospitalized U.S. Adults With Hepatorenal Syndrome-Acute Kidney Injury Treated with Terlipressin: A Retrospective Cohort Study

• Authors: A. Sidney Barritt IV, MD; Kavish R. Patidar, DO; Robert J. Wong, MD, MS; Xingyue Huang, PhD; Rachel Black, PharmD; Mary Panaccio, PhD; Jonathan Lilley, BA; Nisha Wadhwani, PhD; Rahul Rajkumar, MD, MPH; Christopher White, MD, MSPH

About Hepatorenal Syndrome-Acute Kidney Injury
Hepatorenal syndrome–acute kidney injury (HRS-AKI) is a life-threatening condition in adults with advanced liver disease that is marked by a rapid decline in kidney function¹ and is associated with high morbidity and mortality.² It is an acute medical emergency that requires hospitalization.³ A U.S. study based on national data revealed that the projected annual number of inpatients diagnosed with HRS has increased between 2018 and 2023, from 42,930 to 63,381.⁴

INDICATION
TERLIVAZ is indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function.

LIMITATION OF USE

• Patients with a serum creatinine >5 mg/dL are unlikely to experience benefit.

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS OR FATAL RESPIRATORY FAILURE

• TERLIVAZ may cause serious or fatal respiratory failure. Patients with volume overload or with acute-on-chronic liver failure (ACLF) Grade 3 are at increased risk. Assess oxygenation saturation (e.g., SpO₂) before initiating TERLIVAZ. 
   
• Do not initiate TERLIVAZ in patients experiencing hypoxia (e.g., SpO₂ <90%) until oxygenation levels improve. Monitor patients for hypoxia using continuous pulse oximetry during treatment and discontinue TERLIVAZ if SpO₂ decreases below 90%.

Contraindications

TERLIVAZ is contraindicated:

• In patients experiencing hypoxia or worsening respiratory symptoms.
• In patients with ongoing coronary, peripheral, or mesenteric ischemia.

Warnings and Precautions

• Serious or Fatal Respiratory Failure: Obtain baseline oxygen saturation and do not initiate TERLIVAZ in hypoxic patients. Monitor patients for changes in respiratory status using continuous pulse oximetry and regular clinical assessments. Discontinue TERLIVAZ in patients experiencing hypoxia or increased respiratory symptoms.
  
  Manage intravascular volume overload by reducing or discontinuing the administration of albumin and/or other fluids and through judicious use of diuretics. Temporarily interrupt, reduce, or discontinue TERLIVAZ treatment until patient volume status improves. Avoid use in patients with ACLF Grade 3 because they are at significant risk for respiratory failure.
   
• Ineligibility for Liver Transplant: TERLIVAZ-related adverse reactions (respiratory failure, ischemia) may make a patient ineligible for liver transplantation, if listed. For patients with high prioritization for liver transplantation (e.g., MELD ≥35), the benefits of TERLIVAZ may not outweigh its risks.
   
• Ischemic Events: TERLIVAZ may cause cardiac, cerebrovascular, peripheral, or mesenteric ischemia. Avoid use of TERLIVAZ in patients with a history of severe cardiovascular conditions or cerebrovascular or ischemic disease. Discontinue TERLIVAZ in patients who experience signs or symptoms suggestive of ischemic adverse reactions.
   
• Embryo-Fetal Toxicity: TERLIVAZ may cause fetal harm when administered to a pregnant woman. If TERLIVAZ is used during pregnancy, the patient should be informed of the potential risk to the fetus.

Adverse Reactions

• The most common adverse reactions (≥10%) include abdominal pain, nausea, respiratory failure, diarrhea, and dyspnea.

Please click here to see full Prescribing Information, including BOXED WARNING.

About Keenova
Keenova Therapeutics is a leading U.S.-focused branded therapeutics company that strives to help patients with rare or unaddressed conditions live happier and healthier lives.

Keenova's rare disease capabilities underpin our diversified brands portfolio, which is focused across a wide range of specialty therapeutic areas of significant unmet need. These include rheumatology, ophthalmology, nephrology, neurology, pulmonology, orthopedics, urology, and neonatal respiratory critical care.

Headquartered in Dublin, Ireland, Keenova benefits from a strong U.S. manufacturing footprint with facilities in Louisiana, New Jersey, New York, Pennsylvania, and Wisconsin. To learn more, please visit www.keenova.com.

Keenova uses its website as a channel of distribution of important company information, such as press releases, investor presentations, and other financial information. It also uses its website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission ("SEC") disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

Information Regarding Forward-Looking Statements
This release contains forward-looking statements, including with regard to TERLIVAZ®, its potential to improve health and treatment outcomes, and its potential impact on patients. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: the effects of emergence from bankruptcy; satisfaction of, and compliance with, regulatory and other requirements; actions of regulatory bodies and other governmental authorities; changes in laws and regulations; changes in market demand; issues with product quality, manufacturing or supply, or patient safety issues or adverse side effects or adverse reactions associated with TERLIVAZ; and other risks and uncertainties identified and described in more detail in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Keenova's most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, its Registration Statement on Form S-4, as amended, filed with the SEC and other filings with the Securities and Exchange Commission (SEC), all of which are available on the SEC's website (www.SEC.gov) and our website (www.keenova.com). The forward-looking statements made herein speak only as of the date hereof and Keenova Therapeutics does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law. Given these uncertainties, one should not put undue reliance on any forward-looking statements.

References

1. Wong RJ, Balasubramanian J, Panaccio M, Huang X. Acute kidney injury and hepatorenal syndrome among hospitalized patients with chronic liver disease. JAMA Netw Open. 2025;8(5):e2511816.
2. Loftus M, Brown RS Jr, El-Farra NS, Owen EJ, Reau N, Wadei HM, Bernstein D. Improving the management of hepatorenal syndrome–acute kidney injury using an updated guidance and a new treatment paradigm. Gastroenterol Hepatol (N Y). 2023;19(9):527-536.
3. National Organization for Rare Disorders. Hepatorenal syndrome. Available at https://rarediseases.org/rare-diseases/hepatorenal-syndrome. Accessed March 17, 2026.
4. Goyes M, et al. Increasing incidence, cost, and mortality of AKI and HRS in hospitalized patients with cirrhosis. JAMA Netw Open. 2025;8(5):e2511822.

Contacts
Media:	Investors:
media.relations@keenova.com	investor.relations@keenova.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/keenova-presents-a-new-terlivaz-terlipressin-clinical-analysis-at-the-shm-converge-302726576.html

SOURCE Keenova Therapeutics

FAQ

What is Keenova (MNK) presenting about TERLIVAZ at SHM Converge 2026?

Keenova is presenting a retrospective cohort study on TERLIVAZ real-world use and outcomes in HRS‑AKI patients. According to the company, the analysis examines how clinicians use TERLIVAZ in hospitalized U.S. adults and associated clinical outcomes.

When and where will Keenova (MNK) present the TERLIVAZ HRS‑AKI analysis?

The presentation will be delivered at SHM Converge, taking place March 29–April 1, 2026. According to the company, the TERLIVAZ analysis is scheduled among the conference sessions during those dates.

What patient population does the TERLIVAZ study presented by Keenova (MNK) focus on?

The study focuses on hospitalized U.S. adults with hepatorenal syndrome‑acute kidney injury (HRS‑AKI) treated with terlipressin. According to the company, it uses a retrospective cohort to assess utilization patterns and outcomes.

Who authored the TERLIVAZ real-world utilization study presented by Keenova (MNK)?

The study authors include A. Sidney Barritt IV, Kavish R. Patidar, Robert J. Wong, and others. According to the company, a multidisciplinary team of clinicians and researchers contributed to the retrospective analysis.

Does Keenova (MNK) claim TERLIVAZ is FDA approved for HRS‑AKI in this announcement?

Yes, the company states TERLIVAZ is the first and only FDA‑approved therapy to improve kidney function in adults with HRS‑AKI. According to the company, that regulatory status distinguishes TERLIVAZ in this indication.